ARTICLE
15 January 2021

PTAB's Decision To Institute CBM Review Not Reviewable By Federal Circuit

WS
Winston & Strawn LLP

Contributor

Winston & Strawn LLP is an international law firm with 15 offices located throughout North America, Asia, and Europe. More information about the firm is available at www.winston.com.
The Federal Circuit considered two questions: 1) whether the Patent Trial and Appeal Board's decision that a patent qualified for covered business method (CBM) review was reviewable on...
United States Intellectual Property
To print this article, all you need is to be registered or login on Mondaq.com.

The Federal Circuit considered two questions: 1) whether the Patent Trial and Appeal Board's decision that a patent qualified for covered business method (CBM) review was reviewable on appeal, and 2) whether to uphold the Board's decision that the patent was patentable. The patent at issue is directed to a two-step communication path through which a remote device communicates with an intermediate node and thereby connects to a central location. For example, the court said a remote transmitter could be used to communicate with an ATM, which would then transmit the information to a central location.

The Federal Circuit had previously remanded the decision to institute to CBM review to the Board, but following an appeal, the Supreme Court remanded the case back to the Federal Circuit for further consideration under its precedential Thryv, Inc. v. Click-to-Call Technologies, LP, 140 S. Ct. 1367 (2020). In that case, the Supreme Court held that the Patent Office's decision whether earlier litigation bars institution of inter partes review is not appealable under 35 U.S.C. § 314(d). On remand, the Federal Circuit held that in light of Thryv, CBM review, which is subject to "a similar, materially identical 'No Appeal' provision in 35 U.S.C. § 324(e)," is also not subject to judicial review. The Federal Circuit held that Thryv "makes clear that the threshold determination that [the patentee's] patent qualifies for CBM review is a decision that is non-appealable . . . ." Sipco at 3.

On the second issue, patentability, the Federal Circuit upheld the Board's obviousness decision, but did not reach its decision of patent-ineligibility under Section 101. The Federal Circuit held that the Board's determination that the '842 patent was obvious over U.S. Patent No. 5,157,687 (Tymes) was supported by substantial evidence.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More